Best Abstracts 2

Stephan Mielke, Matteo Doglio

Ugur Uslu, Janaki Manoja Vinnakota, Catherine Thieblemont, Natalia Tovar, Aina Oliver-Caldes, Borja Puertas, Friederike Schmitz

February 16, 2024

Presentation of the best abstracts chaired by Dr Stephan Mielke and Dr Matteo Doglio.

STING agonist-mediated IL-18 induction enhances CAR T cell function in solid tumors - Ugur Uslu

Decoding ICANS: Microglial TGF-β-activated kinase-1 signaling mediates neurocognitive deficits after CD19 CAR-T cell therapy - Janaki Manoja Vinnakota

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-up - Catherine Thieblemont

Seven-Day Vein-to-Vein Point-of-Care–Manufactured CD19 CAR T-Cell Therapy (GLPG5201) in R/R CLL Including Richter Transformation: Results from the Phase 1 Euplagia-1 Trial - Natalia Tovar

TIGIT blockade in ARI0002h academic BCMA CART shows improved disease control in a multiple myeloma relapse disease model - Aina Oliver-Caldes

T-cell targeted therapies in triple-class refractory multiple myeloma: sequence matters - Borja Puertas

IMA203 TCR-T-cell therapy targeting PRAME in combination with BRAF-/MEK-inhibition in a melanoma patient with active CNS metastases – A case report - Friederike Schmitz

Don’t miss the Q&A at the end of each presentation.


Presentations

TIGIT blockade in ARI0002h academic BCMA CART shows improved disease control in a multiple myeloma relapse disease model  - Aina Oliver-Caldes

STING agonist-mediated IL-18 induction enhances CAR T cell function in solid tumors - Ugur Uslu

Pathophysiology of ICANS Is Mediated by Microglia Activation - Janaki Manoja Vinnakota

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-up - Catherine Thieblemont

Seven-Day Vein-to-Vein Point-of-Care–Manufactured CD19 CAR T-Cell Therapy (GLPG5201) in R/R CLL Including Richter Transformation: Results from the Phase 1 Euplagia-1 Trial - Natalia Tovar

T-cell targeted therapies in triple-class refractory multiple myeloma: sequence matters - Borja Puertas

IMA203 TCR-T-cell therapy targeting PRAME in combination with BRAF-/MEK-inhibition in a melanoma patient with active CNS metastases – A case report - Friederike Schmitz